UA116125C2 - Інгібітори cdc7 - Google Patents
Інгібітори cdc7Info
- Publication number
- UA116125C2 UA116125C2 UAA201508675A UAA201508675A UA116125C2 UA 116125 C2 UA116125 C2 UA 116125C2 UA A201508675 A UAA201508675 A UA A201508675A UA A201508675 A UAA201508675 A UA A201508675A UA 116125 C2 UA116125 C2 UA 116125C2
- Authority
- UA
- Ukraine
- Prior art keywords
- cdc7 inhibitors
- cdc7
- inhibitors
- useful
- pharmaceutically acceptable
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 102100034744 Cell division cycle 7-related protein kinase Human genes 0.000 abstract 1
- 101000945740 Homo sapiens Cell division cycle 7-related protein kinase Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- PXZQEOJJUGGUIB-UHFFFAOYSA-N isoindolin-1-one Chemical class C1=CC=C2C(=O)NCC2=C1 PXZQEOJJUGGUIB-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epidemiology (AREA)
Abstract
Цей винахід пропонує ізоіндолінонові сполуки або їх фармацевтично прийнятні солі, які пригнічують CDC7 і отже можуть бути корисними при лікуванні раку.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361782798P | 2013-03-14 | 2013-03-14 | |
| US201361789108P | 2013-03-15 | 2013-03-15 | |
| PCT/US2014/021466 WO2014143601A1 (en) | 2013-03-14 | 2014-03-07 | CDC7 Inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA116125C2 true UA116125C2 (uk) | 2018-02-12 |
Family
ID=50382704
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA201508675A UA116125C2 (uk) | 2013-03-14 | 2014-03-07 | Інгібітори cdc7 |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US9156824B2 (uk) |
| EP (1) | EP2970221B1 (uk) |
| JP (1) | JP6064079B2 (uk) |
| KR (1) | KR101718645B1 (uk) |
| CN (1) | CN105008351B (uk) |
| AP (1) | AP2015008734A0 (uk) |
| AU (1) | AU2014228374B2 (uk) |
| BR (1) | BR112015020466B1 (uk) |
| CA (1) | CA2900773C (uk) |
| CL (1) | CL2015002530A1 (uk) |
| CR (1) | CR20150416A (uk) |
| CY (1) | CY1119199T1 (uk) |
| DK (1) | DK2970221T3 (uk) |
| EA (1) | EA027012B1 (uk) |
| ES (1) | ES2639793T3 (uk) |
| GT (1) | GT201500263A (uk) |
| HR (1) | HRP20171151T1 (uk) |
| HU (1) | HUE033482T2 (uk) |
| IL (1) | IL240962B (uk) |
| JO (1) | JO3383B1 (uk) |
| LT (1) | LT2970221T (uk) |
| ME (1) | ME02805B (uk) |
| MX (1) | MX363438B (uk) |
| MY (1) | MY188145A (uk) |
| NZ (1) | NZ710392A (uk) |
| PE (1) | PE20151654A1 (uk) |
| PH (1) | PH12015502091B1 (uk) |
| PL (1) | PL2970221T3 (uk) |
| PT (1) | PT2970221T (uk) |
| RS (1) | RS56122B1 (uk) |
| SG (1) | SG11201507541PA (uk) |
| SI (1) | SI2970221T1 (uk) |
| TN (1) | TN2015000349A1 (uk) |
| TW (1) | TWI622396B (uk) |
| UA (1) | UA116125C2 (uk) |
| WO (1) | WO2014143601A1 (uk) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2906555T3 (en) * | 2012-10-15 | 2017-02-06 | Pfizer Ireland Pharmaceuticals | Process for the preparation of voriconazole and analogs thereof |
| JP6437452B2 (ja) | 2013-01-14 | 2018-12-12 | インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ | Ｐｉｍキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物 |
| LT2945939T (lt) | 2013-01-15 | 2020-07-27 | Incyte Holdings Corporation | Triazolkarboksamidai ir piridinkarboksamido junginiai, naudotini kaip pim kinazės inhibitoriai |
| JP6294953B2 (ja) | 2013-03-14 | 2018-03-14 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｐ２ｘ７調節物質 |
| TWI627174B (zh) | 2013-03-14 | 2018-06-21 | 比利時商健生藥品公司 | Ｐ２ｘ７調控劑 |
| DK2970283T3 (da) | 2013-03-14 | 2021-01-25 | Boehringer Ingelheim Int | Substituerede 2-aza-bicyclo[2.2.1]heptan-3-carboxylsyre-(benzyl-cyano-methyl)-amider som inhibitorer af cathepsin-c |
| ES2689526T3 (es) | 2013-03-14 | 2018-11-14 | Janssen Pharmaceutica Nv | Moduladores de P2X7 |
| TWI599567B (zh) | 2013-03-14 | 2017-09-21 | 健生藥品公司 | Ｐ２ｘ７調節劑 |
| EP3036238A1 (en) | 2013-08-23 | 2016-06-29 | Incyte Corporation | Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors |
| US9822124B2 (en) | 2014-07-14 | 2017-11-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| EP3191492B1 (en) | 2014-09-12 | 2019-01-09 | Janssen Pharmaceutica NV | P2x7 modulators |
| WO2016039983A1 (en) | 2014-09-12 | 2016-03-17 | Janssen Pharmaceutica Nv | P2x7 modulating n-acyl-triazolopyrazines |
| KR102510588B1 (ko) | 2014-09-12 | 2023-03-17 | 베링거 인겔하임 인터내셔날 게엠베하 | 카텝신 c의 스피로사이클릭 억제제 |
| US9540347B2 (en) | 2015-05-29 | 2017-01-10 | Incyte Corporation | Pyridineamine compounds useful as Pim kinase inhibitors |
| AR105967A1 (es) | 2015-09-09 | 2017-11-29 | Incyte Corp | Sales de un inhibidor de pim quinasa |
| WO2017059251A1 (en) | 2015-10-02 | 2017-04-06 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
| CN110036006B (zh) * | 2016-09-22 | 2022-12-13 | 癌症研究科技有限公司 | 嘧啶酮衍生物的制备和用途 |
| TW201924683A (zh) | 2017-12-08 | 2019-07-01 | 美商英塞特公司 | 用於治療骨髓增生性贅瘤的低劑量組合療法 |
| CN108383771A (zh) * | 2018-01-08 | 2018-08-10 | 华东师范大学 | 手性3,3-二取代异吲哚啉-1-酮衍生物及其合成方法和应用 |
| GB201807147D0 (en) | 2018-05-01 | 2018-06-13 | Oncologica Uk Ltd | Therapeutic combination |
| NL2021185B1 (en) | 2018-06-26 | 2020-01-06 | Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis | Combination Therapy and Use Thereof for Treating Cancer |
| CA3111309A1 (en) | 2018-09-28 | 2020-04-02 | Janssen Pharmaceutica Nv | Monoacylglycerol lipase modulators |
| CN113164459B (zh) | 2018-09-28 | 2024-09-03 | 詹森药业有限公司 | 单酰基甘油脂肪酶调节剂 |
| US20220220125A1 (en) * | 2019-04-16 | 2022-07-14 | Janssen Pharmaceutica Nv | Fused isoindolin-1-one derivatives useful as grk2 inhibitors |
| CA3156100A1 (en) | 2019-09-30 | 2021-04-08 | Janssen Pharmaceutica Nv | Radiolabelled mgl pet ligands |
| CA3176946A1 (en) | 2020-03-26 | 2021-09-30 | Janssen Pharmaceutica Nv | Monoacylglycerol lipase modulators |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0400970D0 (sv) * | 2004-04-14 | 2004-04-14 | Astrazeneca Ab | Nicotinic acetylcholine receptor ligands |
| TW200639163A (en) * | 2005-02-04 | 2006-11-16 | Genentech Inc | RAF inhibitor compounds and methods |
| US7576082B2 (en) * | 2005-06-24 | 2009-08-18 | Hoffman-La Roche Inc. | Oxindole derivatives |
| ATE545416T1 (de) * | 2006-10-12 | 2012-03-15 | Xenon Pharmaceuticals Inc | Verwendung von spiro-oxindol-verbindungen als therapeutika |
| US8648069B2 (en) | 2007-06-08 | 2014-02-11 | Abbvie Inc. | 5-substituted indazoles as kinase inhibitors |
| WO2008154241A1 (en) * | 2007-06-08 | 2008-12-18 | Abbott Laboratories | 5-heteroaryl substituted indazoles as kinase inhibitors |
-
2014
- 2014-03-04 JO JOP/2014/0067A patent/JO3383B1/ar active
- 2014-03-05 TW TW103107546A patent/TWI622396B/zh active
- 2014-03-07 DK DK14712966.2T patent/DK2970221T3/en active
- 2014-03-07 CA CA2900773A patent/CA2900773C/en active Active
- 2014-03-07 KR KR1020157024644A patent/KR101718645B1/ko active Active
- 2014-03-07 HR HRP20171151TT patent/HRP20171151T1/hr unknown
- 2014-03-07 HU HUE14712966A patent/HUE033482T2/en unknown
- 2014-03-07 NZ NZ710392A patent/NZ710392A/en unknown
- 2014-03-07 LT LTEP14712966.2T patent/LT2970221T/lt unknown
- 2014-03-07 ME MEP-2017-173A patent/ME02805B/me unknown
- 2014-03-07 WO PCT/US2014/021466 patent/WO2014143601A1/en not_active Ceased
- 2014-03-07 EP EP14712966.2A patent/EP2970221B1/en active Active
- 2014-03-07 MX MX2015012583A patent/MX363438B/es unknown
- 2014-03-07 RS RS20170791A patent/RS56122B1/sr unknown
- 2014-03-07 ES ES14712966.2T patent/ES2639793T3/es active Active
- 2014-03-07 BR BR112015020466-0A patent/BR112015020466B1/pt active IP Right Grant
- 2014-03-07 PL PL14712966T patent/PL2970221T3/pl unknown
- 2014-03-07 SI SI201430280T patent/SI2970221T1/sl unknown
- 2014-03-07 SG SG11201507541PA patent/SG11201507541PA/en unknown
- 2014-03-07 US US14/200,141 patent/US9156824B2/en active Active
- 2014-03-07 UA UAA201508675A patent/UA116125C2/uk unknown
- 2014-03-07 AP AP2015008734A patent/AP2015008734A0/xx unknown
- 2014-03-07 MY MYPI2015703062A patent/MY188145A/en unknown
- 2014-03-07 AU AU2014228374A patent/AU2014228374B2/en active Active
- 2014-03-07 JP JP2016500764A patent/JP6064079B2/ja active Active
- 2014-03-07 PE PE2015001925A patent/PE20151654A1/es active IP Right Grant
- 2014-03-07 PT PT147129662T patent/PT2970221T/pt unknown
- 2014-03-07 EA EA201591509A patent/EA027012B1/ru not_active IP Right Cessation
- 2014-03-07 CN CN201480011202.4A patent/CN105008351B/zh active Active
-
2015
- 2015-08-12 TN TN2015000349A patent/TN2015000349A1/en unknown
- 2015-08-14 CR CR20150416A patent/CR20150416A/es unknown
- 2015-08-31 IL IL240962A patent/IL240962B/en active IP Right Grant
- 2015-09-09 CL CL2015002530A patent/CL2015002530A1/es unknown
- 2015-09-09 GT GT201500263A patent/GT201500263A/es unknown
- 2015-09-14 PH PH12015502091A patent/PH12015502091B1/en unknown
-
2017
- 2017-08-10 CY CY20171100861T patent/CY1119199T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015502091A1 (en) | Cdc7 inhibitors | |
| PH12017500881B1 (en) | Aurora a kinase inhibitor | |
| IL256874B (en) | Immune checkpoint suppressors for use in the treatment of blood-borne cancers | |
| EP3247353A4 (en) | Heterocyclic itk inhibitors for treating inflammation and cancer | |
| MX2016015181A (es) | Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer. | |
| IL268430A (en) | Methods for treating cancer using hsp90 inhibitors | |
| PH12017500621A1 (en) | Triazolopyrazinones as pde1 inhibitors | |
| MX369691B (es) | Inhibidores de glutaminasa y métodos de empleo. | |
| PH12016500270A1 (en) | Combination of a mek inhibitor and an erk inhibitor for use in treatment of hyperproliferative diseases | |
| SG10201808940WA (en) | Nox inhibitor and nfкb inhibitor containing methoxyflavone | |
| WO2014165090A8 (en) | Compounds for the treatment of tuberculosis | |
| EP3664803A4 (en) | DHODH INHIBITOR FOR USE IN THE TREATMENT OF HEMATOLOGICAL CANCERS | |
| EP3131552A4 (en) | Methods for treating cancer using tor kinase inhibitor combination therapy | |
| GB201702160D0 (en) | Inhibitors for use in therapy | |
| PH12016501173A1 (en) | Quinazolin-thf-amines as pde1 inhibitors | |
| MX2015013021A (es) | 5-bromo-indirrubinas. | |
| PH12016501495A1 (en) | Hexahydrofuropyrroles as pde1 inhibitors | |
| NZ711523A (en) | Use of sedoheptulose for prevention or treatment of inflammation | |
| WO2014160628A3 (en) | Articles and methods for preventing and treating dermatologic adverse events | |
| EP3025711A4 (en) | Medicine for preventing or treating hypertension | |
| EP3674398A4 (en) | ECHOVIRUS FOR TUMOR TREATMENT | |
| EP3131550A4 (en) | Methods for treating cancer using tor kinase inhibitor combination therapy | |
| HK40031759A (en) | Dhodh inhibitor for use in treating hematologic cancers | |
| HK1261928A1 (en) | Combination therapy for treating malignancies | |
| HK1259979A1 (en) | Combination therapy for treating malignancies |